undamentalytics Newsletter
Sign in

NRX Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, NRX Pharmaceuticals, Inc. had total assets of $13.0m, total liabilities of $28.9m and shareholders' equity of −$15.9m. It held $7.8m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents51827
Receivables0000
Total current assets73929
Goodwill—022
Total assets741334
Accounts payable5443
Total current liabilities19222934
Short-term debt9———
Long-term debt950—
Total debt11600
Total liabilities19272934
Shareholders' equity−12−23−16−0
Shares outstanding17m——43m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: NRXP vs XBIONRXP vs UPBALGS vs NRXP

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from NRX Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to NRX Pharmaceuticals, Inc.